Corneal opacification inhibitory composition
US5710148A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 4, 1996 |
| Grant date | Jan 20, 1998 |
| Priority date | — |
| Expiry date | Mar 4, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/336
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An ophthalmic preparation which comprises a fumagillol derivative represented by the general formula(I): ##STR1## wherein R.sup.1 is hydrogen; R.sup.2 is a halogen, N(O).sub.m R.sup.5 R.sup.6, N.sup.+ R.sup.5 R.sup.6 R.sup.7 .multidot.X.sup.-, S(O).sub.n R.sup.5 or S.sup.+ R.sup.5 R.sup.6 .multidot.X.sup.-, wherein R.sup.5, R.sup.6 and R.sup.7 represent independently a substituted or unsubstituted hydrocarbon group or a substituted or unsubstituted heterocyclic group; X.sup.- represents a counter anion; m represents 0 or 1; n represents an integer from 0 to 2; or R.sup.5 and R.sup.6 together with the adjacent nitrogen or sulfur atom may form a substituted or unsubstituted nitrogen- or sulfur-containing heterocyclic group which may form a condensed ring; or R.sup.1 and R.sup.2 are combined to represent a chemical bond; R.sup.3 is a substituted or unsubstituted 2-methyl-l-propenyl group or a substituted or unsubstituted isobutyl group; A is oxygen or NR.sup.8, wherein R.sup.8 represents hydrogen, a substituted or unsubstituted lower alkyl group or a substituted or unsubstituted aryl group; and R.sup.4 is hydrogen, a substituted or unsubstituted hydrocarbon group or a substituted or u…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.